Myrtelle Announces that the FDA has Selected rAAV-Olig001-ASPA Gene Therapy Candidate for the Treatment of Canavan Disease for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program
Article Date
June 5, 2024
This article is featured on another website.
Go to article
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…
May 26, 2026
Closing the Cross-Border Gap for Global Trials
Closing the Cross-Border Gap: Why Modern Global CROs Must Link Regulatory Strategy to Multi-Region Execution.…
May 26, 2026
Closing the Cross-Border Gap for Global Trials
Closing the Cross-Border Gap: Why Modern Global CROs Must Link Regulatory Strategy to Multi-Region Execution.…